{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43.4","upperLimit":"63.0","value":"53.3"}]}],"title":"Course 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"58.2","upperLimit":"77.4","value":"68.4"}]}],"title":"Course 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"69.3","upperLimit":"87.3","value":"79.3"}]}],"title":"Course 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43.3","upperLimit":"67.6","value":"55.7"}]}],"title":"Course 4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"109"}],"units":"Participants"}],"description":"Adverse events are reported for patients receiving concurrent irinotecan hydrochloride and radiotherapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Parameningeal (without intracranial extension) and paraspinal tumors receive chemotherapy starting Week 1 and begin radiation therapy at Week 20. Weeks 1-6: vincristine sulfate and irinotecan hydrochloride. Weeks 7-34: vincristine sulfate and irinotecan hydrochloride, Cyclophosphamide with MESNA, Doxorubicin hydrochloride, Etoposide, Ifosfamide with MESNA. Weeks 35-54: vincristine sulfate, Dactinomycin, irinotecan hydrochloride and Cyclophosphamide with MESNA and Filgrastim. Radiation therapy beginning at Week 20. Second look conventional surgery: Surgical resection other than biopsy will be applicable for the majority of patients.","id":"OG000","title":"High_Risk_Rhabdomyosarcoma"}],"paramType":"NUMBER","populationDescription":"Percentage of patients experiencing a grade 3/4/5 toxicity in a course.","reportingStatus":"POSTED","timeFrame":"From enrollment to up to 2 years","title":"Percentage of Patients Experiencing Adverse Events Due to Concurrent Therapy","type":"PRIMARY","unitOfMeasure":"percentage of patients"}